Literature DB >> 23152551

Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA.

S Pas1, R Molenkamp, J Schinkel, S Rebers, C Copra, S Seven-Deniz, D Thamke, R J de Knegt, B L Haagmans, M Schutten.   

Abstract

To evaluate the analytical performance and explore the clinical applicability of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, v2.0 (CAP/CTM v2.0), a platform comparison was performed on panels and diagnostic samples with the Roche cobas AmpliPrep/cobas TaqMan HCV test (CAP/CTM v1.0), the Siemens Versant HCV RNA 3.0 branched DNA (bDNA) test, the Abbott m2000 RealTime HCV assay (Realtime assay), and the Siemens Versant HCV transcription-mediated amplification (TMA) test (TMA assay). The analytical performance of the CAP/CTM v2.0 on WHO and Acrometrix panels and clinical specimens of patients infected with HCV genotype 1, 2, 3, 4, 5, or 6 relative to that of the CAP/CTM v1.0 was significantly improved. In a qualitative comparison of the CAP/CTM v2.0 relative to the TMA assay on genotype 1 to 4 samples, the two tests proved to be almost equally sensitive. Response-guided therapy in one of five HCV genotype 4-infected patients previously tested with the CAP/CTM v1.0 would have significantly changed if tested with the CAP/CTM v2.0. In conclusion, the Roche CAP/CTM v2.0 has significantly better performance characteristics than the former CAP/CTM HCV v1.0 and the bDNA assay and performance characteristics comparable to those of the Realtime assay.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23152551      PMCID： PMC3536185          DOI： 10.1128/JCM.01729-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Clinical utility of viral quantification as a tool for disease monitoring.

Authors:  M Schutten; H G Niesters
Journal:  Expert Rev Mol Diagn       Date:  2001-07       Impact factor: 5.225

2.  Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA.

Authors:  J Kleiber; T Walter; G Haberhausen; S Tsang; R Babiel; M Rosenstraus
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

3.  Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions.

Authors:  Suwanna Noppornpanth; Erwin Sablon; Kathy De Nys; Xuan Lien Truong; Jan Brouwer; Marianne Van Brussel; Saskia L Smits; Yong Poovorawan; Albert D M E Osterhaus; Bart L Haagmans
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

4.  Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

Authors:  Cheryl Jennings; Brian Harty; Suzanne Granger; Carrie Wager; John A Crump; Susan A Fiscus; James W Bremer
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

5.  Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA.

Authors:  David A Hendricks; Michel Friesenhahn; Lorine Tanimoto; Bernd Goergen; Deborah Dodge; Lorraine Comanor
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

6.  Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study.

Authors:  G Colucci; J Ferguson; C Harkleroad; S Lee; D Romo; S Soviero; J Thompson; M Velez; A Wang; Y Miyahara; S Young; C Sarrazin
Journal:  J Clin Microbiol       Date:  2007-09-26       Impact factor: 5.948

7.  Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification.

Authors:  Gregg Gorrin; Michel Friesenhahn; Patsy Lin; Marla Sanders; Reinhold Pollner; Brandon Eguchi; Jimmykim Pham; Gianluca Roma; Joseph Spidle; Susann Nicol; Carol Wong; Suvarna Bhade; Lorraine Comanor
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

9.  Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system.

Authors:  Dorothea Sizmann; Claudia Boeck; Juergen Boelter; Daniela Fischer; Marion Miethke; Stefan Nicolaus; Markus Zadak; Reiner Babiel
Journal:  J Clin Virol       Date:  2007-03-06       Impact factor: 3.168

10.  Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences.

Authors:  Donald G Murphy; Bernard Willems; Marc Deschênes; Nir Hilzenrat; Roger Mousseau; Sidney Sabbah
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948
View more
  8 in total

1.  Implementation and Preliminary Results of an Emergency Department Nontargeted, Opt-out Hepatitis C Virus Screening Program.

Authors:  Elissa M Schechter-Perkins; Nancy S Miller; Jon Hall; Joshua J Hartman; David H Dorfman; Chris Andry; Benjamin P Linas
Journal:  Acad Emerg Med       Date:  2018-07-20       Impact factor: 3.451

2.  COBAS ® AmpliPrep/COBAS ® Taqman ® HCV Quantitative Test, version 2.0: an in vitro test for hepatitis C virus RNA quantification.

Authors:  Emma D Deeks
Journal:  Mol Diagn Ther       Date:  2015-02       Impact factor: 4.074

Review 3.  Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment.

Authors:  Hans L Tillmann
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 4.  Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.

Authors:  Verónica Saludes; Victoria González; Ramon Planas; Lurdes Matas; Vicente Ausina; Elisa Martró
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

5.  Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France.

Authors:  Pierre Cappy; Laure Boizeau; Daniel Candotti; Rémi Caparros; Quentin Lucas; Eliane Garrabe; Christophe Martinaud; Sophie Le Cam; Pierre Gallian; Pascal Morel; Josiane Pillonel; Syria Laperche
Journal:  Blood Transfus       Date:  2021-05-12       Impact factor: 3.443

Review 6.  Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection.

Authors:  Marco Ciotti; Cartesio D'Agostini; Aldo Marrone
Journal:  Gastroenterology Res       Date:  2013-10-31

Review 7.  Quantitative nucleic acid amplification methods and their implications in clinical virology.

Authors:  Mini P Singh; Shipra Galhotra; Karnika Saigal; Archit Kumar; Radha Kanta Ratho
Journal:  Int J Appl Basic Med Res       Date:  2017 Jan-Mar

Review 8.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.